ClinicalTrials.gg
RecruitingNCT06508255Updated Jul 18, 2024

Time-restricted Eating and Cognition

An interventional study of Early Time-Restricted Eating and Late Time-Restricted Eating in Time Restricted Eating and Intermittent Fasting, sponsored by German Institute of Human Nutrition. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by German Institute of Human Nutrition · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Intermittent Fasting with a site in Germany — 9 open to participants now, 9 under way, none of them phase 3. Intermittent Fasting · Germany.

Planned enrollment
8th of 13
35 · median 50
Started
2024
the only one that year
No phase
13 of 15
9 open now
Registered
9th of 15
by date
Lead sponsor
3 of 15
German Institute of Human Nutrition

Among the 15 studies in Intermittent Fasting with a site in Germany, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 9th registered.

Intermittent Fasting

334 studies on the registry are indexed under Intermittent Fasting; 100 are open to participants now.

Browse Intermittent Fasting studies →

Open to participants now

9 of the 15 studies in Intermittent Fasting with a site in Germany are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 73 Intermittent Fasting studies recruiting now, 19 (26%) set no upper age limit and 48 (66%) stop at 75 or younger; 4 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Intermittent Fasting with a site in Germany, or all of them as a file.
02

Study summary

This study aims to investigate how time-restricted eating (TRE), more specifically TRE at different times (early vs late in the day), influences brain activity, behavior, decision-making, food intake, physical activity, the gut microbiome and metabolic processes. The study intervention procedure is a replication of that described in Peters et al. (2021).

Read the detailed description

This study aims to investigate the effects of different time-restricted eating (TRE) interventions on decision-making, brain activity and related processes in an all female cohort over 8 weeks. The study will have a within-subjects, randomised, crossover design, involving two TRE interventions with a comparable feeding and fasting window of 8:16h respectively- early TRE (eating window: 08:00-16:00) and late TRE (eating window: 13:00-21:00). After completing a screening visit, participants will complete a two-week observational phase in which they record their habitual food intake, as well as sleep and physical activity assessment. After this observational phase, participants will be randomly assigned to one of two study arms (early TRE/late TRE or late TRE/early TRE). Here they will complete both TRE interventions for two weeks each, separated by a washout phase of two weeks. During these phases they will record their food intake and physical activity and sleep will be assessed. The participants will be invited for 4 laboratory study visits during this time, at the beginning and end of each TRE intervention.

03

Conditions studied

  • Time Restricted Eating
  • Intermittent Fasting

Keywords

  • Time-restricted eating
  • Time-restricted feeding
  • Cognition
  • Decision-making
  • Behaviour
  • Brain Activity
  • Food Intake
  • Diet
  • Microbiome
  • Sleep
  • Physical Activity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • right-handed
  • legally competent
  • physically and mentally healthy
  • : 19-35 kg/m²
  • fluent in reading and speaking German

Exclusion criteria

Exclusion Criteria:

  • weight change >5% of body weight during the last 3 months
  • pregnancy or breastfeeding
  • allergies (inclusion possible after consultation with study doctor)
  • history of cardiovascular disease (myocardial infarction, stroke, hypertension, hypotension) in the last year
  • severe psychiatric condition, including drug addiction and depression
  • impaired renal or liver function
  • dementia or other severely debilitating cognitive disease
  • history of or current eating disorders (e.g., Bulimia nervosa, Anorexia nervosa, Orthorexia nervosa, Binge-Eating disorder)
  • chronic diseases (e.g., Morbus Crohn, Colitis Ulcerosa)
  • metabolic disorders (e.g., metabolic syndrome, diabetes type 1 or 2)
  • hormonal imbalances (e.g., thyroid gland diseases)
  • consuming diseases (e.g., cancer, kachexie) in the last 2 years
  • surgical removal (partial removal) of the digestive organs (e.g., gastrectomy) or history of bariatric surgery
  • conditions or current infection
  • Blood clotting disorders (e.g., haemophilia)
  • Severe anemia
  • severe claustrophobia
  • blood donation four weeks prior to study entry
  • therapy (oral)
  • anticoagulant medication (inclusion possible if medication can be paused)
  • taking medications that require regular eating
  • any medications or supplements known to affect sleep, circadian rhythms, immune activity or metabolism
  • taking weight loss, lipid or glucose-lowering medications (any medications that affects metabolism) i.e. metformin
  • pacemaker or other electrical implant
  • vaccination during the study course or in the two weeks' prior
  • premedication
  • currently on a diet/fasting regime (or within 1 month)
  • professional athletes
  • nicotine consumption
  • drug abuse
  • alcohol consumption per week more than 14 beers (0,3l)/ wine (0,125l)/ sparkling wine (0,1l)/Schnaps (4cl)
  • shift work
  • poor sleep quality (PSQI score > 10 at medical screening)
  • travel across more than one time zone one month before study or during study period
  • non-removable metallic implants
  • fear of blood draw
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Early Time-Restricted Eating

    Behavioral: Early Time-Restricted Eating

  • Experimental
    Late Time-Restricted Eating

    Behavioral: Late Time-Restricted Eating

Interventions

  • BehavioralEarly Time-Restricted Eating

    Eat between 8:00 and 16:00 for 2 weeks

    Also known as: early TRE, eTRE, eTRF

  • BehavioralLate Time-Restricted Eating

    Eat between 13:00 and 21:00 for 2 weeks

    Also known as: late TRE, lTRE, lTRF

06

What researchers measure

Primary outcomes

  1. Behaviour: risk propensity on a decision-making task

    The choice (accept/reject) between a risk/gamble or safe option, based on a task paradigm by Liu et al. (2021)

    Time frame: 8 weeks

  2. Brain: blood-oxygen-level-dependent (BOLD) signal changes

    BOLD signal changes on a whole-brain level and in predefined regions of interest assessed using fMRI

    Time frame: 8 weeks

  3. Behaviour: Daily food intake

    Self-reported food intake, recorded via FoodApp or handwritten food diary

    Time frame: 8 weeks

  4. Large Neutral Amino Acids (LNAAs)

    Blood samples

    Time frame: 8 weeks

  5. Fasting glucose

    Blood samples

    Time frame: 8 weeks

  6. Insulin

    Blood samples

    Time frame: 8 weeks

Secondary outcomes

  1. Questionnaire assessing sleep quality

    Assessed by the Pittsburgh Sleep Quality Index (PSQI, Buysse et al. 1991). The questionnaire is scored between 0-21, with a higher value indicating worse sleep quality

    Time frame: 8 weeks

  2. Total Sleep Time (TST)

    Assessed through an ActiGraph device

    Time frame: 8 weeks

  3. Sleep Efficiency (SE)

    Assessed through an ActiGraph device

    Time frame: 8 weeks

  4. Wake After Sleep Onset (WASO)

    Assessed through an ActiGraph device Sleep Onset Latency (SOL), Sleep Fragmentation Index

    Time frame: 8 weeks

  5. Sleep Onset Latency (SOL)

    Assessed through an ActiGraph device

    Time frame: 8 weeks

  6. Sleep Fragmentation Index

    Assessed through an ActiGraph device

    Time frame: 8 weeks

  7. Glucose tolerance

    Assessed using an Oral Glucose Tolerance Test (OGTT). 5 blood samples will be carried out (fasted, 30 minutes, 60 minutes 120 minutes, 180 minutes after glucose consumption). Using these 5 values, area under curve (AUC) will be calculated to determine glucose tolerance

    Time frame: 8 weeks

  8. Total movement

    24h activity, assessed using an ActiGraph device

    Time frame: 8 weeks

  9. Moderate to Vigorous Physical Activity (MVPA)

    24h activity, assessed using an ActiGraph device

    Time frame: 8 weeks

  10. Non-sedentary Time

    24h activity, assessed using an ActiGraph device

    Time frame: 8 weeks

  11. Step Count

    24h activity, assessed using an ActiGraph device

    Time frame: 8 weeks

  12. Energy Expenditure

    24h activity, assessed using an ActiGraph device

    Time frame: 8 weeks

  13. Daily questions monitoring intervention effects

    Daily self-report questions of experience during intervention, level of physical activity, sleep quality, hunger and appetite levels, sleep and physical activity using Visual Analog Scales (VAS with a scale of 1-100, where higher values correspond to stronger e.g. hunger)

    Time frame: 8 weeks

  14. Questionnaires assessing chronotype

    Munich Chronotype Questionnaire (MCTQ, Roenneberg et al. 2003), Morningness Eveningness Questionnaire (MEQ, Horne et al.1976)

    Time frame: 8 weeks

  15. Questionnaire assessing risk-taking behaviour

    Domain Specific Risk-Taking (DOSPERT, Johnson et al. 2004)

    Time frame: 8 weeks

  16. Questionnaire assessing stress

    Perceived Stress Questionnaire (PSQ, Fliege et al. 2001)

    Time frame: 8 weeks

  17. Questionnaire assessing intuitive eating

    Intuitive Eating Scale (IES-2, Ruzanska et al. 2017)

    Time frame: 8 weeks

  18. Questionnaire assessing emotional eating

    Salzburg Emotional Eating Questionnaire (SEES, Meule et al. 2018)

    Time frame: 8 weeks

  19. Questionnaire assessing food cravings

    Food Cravings Questionnaire (FCQ, Meule et al. 2012)

    Time frame: 8 weeks

  20. Questionnaire assessing impulsive behaviour

    Barratt Impulsivity Scale (BIS, Meule et al. 2011)

    Time frame: 8 weeks

  21. Questionnaire assessing momentary impulsive behaviour

    Momentary Impulsivity Assessment (Tomko et al., 2014)

    Time frame: 8 weeks

  22. Questionnaire assessing behavioural inhibition and activation

    Behavioural Inhibition and Activation (BIS/BAS, Strobel et al. 2001)

    Time frame: 8 weeks

  23. Questionnaire assessing mood

    Positive and Negative Affect Scale (PANAS, Janke et al. 2014)

    Time frame: 8 weeks

  24. Questionnaire assessing interoception

    Multidimension Assessment of Interoceptive Awareness (MAIA-2, Mehling et al. 2018)

    Time frame: 8 weeks

  25. Questionnaire assessing social decision-making

    Social Value Orientation (SVO, Murphy et al. 2011)

    Time frame: 8 weeks

  26. Questionnaire assessing wellbeing

    Warwick Edinburgh Mental Wellbeing Scale (WEMWBS, Lang et al. 2017)

    Time frame: 8 weeks

  27. Gut microbiome composition

    Collection of stool samples before and after each intervention to assess gut microbiome composition including alpha and beta diversity

    Time frame: 8 weeks

  28. Decision-making

    Delay discounting task: the task involves making choices between receiving two hypothetical monetary amounts: an immediate but smaller sum of money or a larger sum of money at a delayed, future point in time. The task paradigm is based on Wan et al. (2023) and Eisenstein et al. (2015).

    Time frame: 8 weeks

  29. Decision-making

    Go/no-go task: the task involves responding to specific visual cues (go trial; press button) or inhibiting a response (no-go trial; don't press button) as fast as possible, assessing inhibitory control and impulsiveness

    Time frame: 8 weeks

  30. Cortisol

    Blood samples

    Time frame: 8 weeks

  31. Progesterone

    Blood samples

    Time frame: 8 weeks

  32. Estradiol

    Blood samples

    Time frame: 8 weeks

  33. Ghrelin

    Blood samples

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • German Institute of Human Nutrition (DIfE)
    Nuthetal, Germany
    Recruiting
08

References and documents

Publications

  • Peters B, Koppold-Liebscher DA, Schuppelius B, Steckhan N, Pfeiffer AFH, Kramer A, Michalsen A, Pivovarova-Ramich O. Effects of Early vs. Late Time-Restricted Eating on Cardiometabolic Health, Inflammation, and Sleep in Overweight and Obese Women: A Study Protocol for the ChronoFast Trial. Front Nutr. 2021 Nov 15;8:765543. doi: 10.3389/fnut.2021.765543. eCollection 2021. PubMed 34869534 ↗
  • Liu L, Artigas SO, Ulrich A, Tardu J, Mohr PNC, Wilms B, Koletzko B, Schmid SM, Park SQ. Eating to dare - Nutrition impacts human risky decision and related brain function. Neuroimage. 2021 Jun;233:117951. doi: 10.1016/j.neuroimage.2021.117951. Epub 2021 Mar 12. PubMed 33722669 ↗
  • Roenneberg T, Wirz-Justice A, Merrow M. Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 2003 Feb;18(1):80-90. doi: 10.1177/0748730402239679. PubMed 12568247 ↗
  • Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. PubMed 1027738 ↗
  • Johnson, J., Wilke, A., & Weber, E. U. (2004). Beyond a trait view of risk taking: A domain-specific scale measuring risk perceptions, expected benefits, and perceived-risk attitudes in German-speaking populations. Polish Psychological Bulletin, 35, 153-172
  • Fliege, H., Rose, M., Arck, P., Levenstein, S., & Klapp, B. F. (2001). Validierung des "perceived stress questionnaire"(PSQ) an einer deutschen Stichprobe. Diagnostica, 47(3), 142-152.
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991 Aug;14(4):331-8. Erratum In: Sleep 1992 Feb;15(1):83. PubMed 1947597 ↗
  • Meule A, Reichenberger J, Blechert J. Development and Preliminary Validation of the Salzburg Emotional Eating Scale. Front Psychol. 2018 Feb 6;9:88. doi: 10.3389/fpsyg.2018.00088. eCollection 2018. PubMed 29467700 ↗
  • Meule, A., Vögele, C. & Kübler, A. Psychometrische Evaluation der deutschen Barratt Impulsiveness Scale - Kurzversion (BIS-15). Diagnostica 57, 126-133 (2011).
  • Janke, S., & Glöckner-Rist, A. (2014). "Deutsche Version der Positive and Negative Affect Schedule (PANAS)" in Zusammenstellung sozialwissenschaftlicher Items und Skalen, GESIS (Mannheim, Germany). doi.org/10.6102/zis146
  • Meule A, Lutz A, Vogele C, Kubler A. Food cravings discriminate differentially between successful and unsuccessful dieters and non-dieters. Validation of the Food Cravings Questionnaires in German. Appetite. 2012 Feb;58(1):88-97. doi: 10.1016/j.appet.2011.09.010. Epub 2011 Sep 29. PubMed 21983051 ↗
  • Strobel, A., Beauducel, A., Debener, S., & Brocke, B. (2001). Eine deutschsprachige version des BIS/BAS-Fragebogens von carver und white. Zeitschrift für Differentielle und diagnostische Psychologie.
  • Eggart M, Todd J, Valdes-Stauber J. Validation of the Multidimensional Assessment of Interoceptive Awareness (MAIA-2) questionnaire in hospitalized patients with major depressive disorder. PLoS One. 2021 Jun 25;16(6):e0253913. doi: 10.1371/journal.pone.0253913. eCollection 2021. PubMed 34170963 ↗
  • Ruzanska UA, Warschburger P. Psychometric evaluation of the German version of the Intuitive Eating Scale-2 in a community sample. Appetite. 2017 Oct 1;117:126-134. doi: 10.1016/j.appet.2017.06.018. Epub 2017 Jun 21. PubMed 28645751 ↗
  • Murphy, R. O., Ackermann, K. A., & Handgraaf, M. J. (2011). Measuring social value orientation. Judgment and Decision making, 6(8), 771-781.
  • Lang, G., & Bachinger, A. (2017). Validation of the German Warwick-Edinburgh mental well-being scale (WEMWBS) in a community-based sample of adults in Austria: a bi-factor modelling approach. Journal of Public Health, 25, 135-146.
  • Eisenstein SA, Gredysa DM, Antenor-Dorsey JA, Green L, Arbelaez AM, Koller JM, Black KJ, Perlmutter JS, Moerlein SM, Hershey T. Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. PLoS One. 2015 Jul 20;10(7):e0133621. doi: 10.1371/journal.pone.0133621. eCollection 2015. Erratum In: PLoS One. 2016 Jan 08;11(1):e0147063. doi: 10.1371/journal.pone.0147063. PubMed 26192187 ↗
  • Tomko RL, Solhan MB, Carpenter RW, Brown WC, Jahng S, Wood PK, Trull TJ. Measuring impulsivity in daily life: the momentary impulsivity scale. Psychol Assess. 2014 Jun;26(2):339-49. doi: 10.1037/a0035083. Epub 2013 Nov 25. PubMed 24274047 ↗
  • Wan H, Myerson J, Green L. Individual differences in degree of discounting: Do different procedures and measures assess the same construct? Behav Processes. 2023 May;208:104864. doi: 10.1016/j.beproc.2023.104864. Epub 2023 Mar 30. PubMed 37001683 ↗

Individual participant data

Plan to share: Yes — Only anonymized data will be shared with the scientific community by making the anonymized data available via public servers (for example, Open Science Framework) when requested.

Supporting information: Statistical analysis plan

Time frame: Fully anonymised data will be available after publication of results when requested.

Access criteria: the anonymized data will be available via public servers (for example, Open Science Framework) when requested.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2025, 10 months after the start.

Of 258 non-industry interventional studies with no phase under Intermittent Fasting, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 10 months is below that.

Counting every sponsor, half of 264 studies reached it within 17 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jul 18, 2024
StartActual
May 17, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06508255
Lead sponsor
German Institute of Human Nutrition
Collaborators
Prof. Dr. Olga Ramich (German Institute of Human Nutrition), Freie Universität Berlin, German Center for Diabetes Research, Charite University, Berlin, Germany
Responsible party
Prof. Dr. Soyoung Q Park (Prof. Dr. Soyoung Q Park (Principal Investigator), German Institute of Human Nutrition) — Principal investigator
First posted
Jul 18, 2024
Start date
May 17, 2024
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Jul 18, 2024

Study contacts

Lara Ryan
Contact
lara.ryan@dife.de
33 200 88 - 2511 ext. + 49
Soyoung Q Park, Prof. Dr.
principal investigator · German Institute of Human Nutrition

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion